Therapeutic Potential of Targeting the PERK Signaling Pathway in Ischemic Stroke

Jamie Chlond^*
*Correspondence: Jamie Chlond, Department of Anesthesia, University Hospital of Grenoble Alpes, Grenoble, France, Email:

Keywords

Therapeutic strategies • Pathophysiology • Ischemic stroke • Stroke management

Introduction

Ischemic stroke accounts for the majority of stroke cases and is characterized by the sudden interruption of blood flow to the brain, leading to neuronal injury and neurological deficits. Current treatment options, including thrombolysis and mechanical thrombectomy, aim to restore cerebral blood flow promptly. However, these interventions have limited efficacy and are often accompanied by adverse effects. There is an urgent need for novel therapeutic approaches to improve outcomes in ischemic stroke patients. The PERK signaling pathway is a crucial component of the Unfolded Protein Response (UPR), a cellular stress response mechanism activated in response to Endoplasmic Reticulum (ER) stress. Under physiological conditions, PERK remains inactive due to its association with the ER chaperone protein, BiP (binding immunoglobulin protein). However, during ER stress, BiP dissociates from PERK, leading to its activation through autophosphorylation [1].

Literature Review

During ischemic stroke, disruption of cerebral blood flow results in oxygen and glucose deprivation, leading to ER stress and activation of the PERK pathway. Activated PERK phosphorylates eukaryotic initiation Factor 2 alpha (eIF2α), leading to global inhibition of protein translation and attenuation of ER stress. Additionally, PERK-mediated signaling regulates various cellular processes, including apoptosis, inflammation and oxidative stress, which contribute to neuronal injury during ischemic stroke. Given the critical role of PERK signaling in ischemic stroke pathophysiology, targeting this pathway represents a promising therapeutic strategy. Several pharmacological agents, including small molecule inhibitors and activators of PERK, have been investigated in preclinical studies. These agents demonstrate neuroprotective effects by attenuating ER stress, reducing neuronal apoptosis and modulating inflammation and oxidative stress [2].

Despite promising preclinical data, translating PERK-targeted therapies into clinical practice faces several challenges. These include off-target effects, limited blood-brain barrier permeability and the need for precise temporal and spatial modulation of PERK activity. Additionally, further research is needed to elucidate the long-term effects and safety profiles of PERK-targeted interventions in ischemic stroke patients. he ischemic microenvironment fosters PERK activation through multiple converging pathways. Hypoxia, oxidative stress, and calcium dysregulation, hallmarks of ischemic injury, contribute to ER stress and PERK activation. Additionally, inflammatory mediators and excitotoxicity further potentiate PERK signaling, exacerbating neuronal damage. Notably, PERK activation not only regulates protein synthesis but also modulates mitochondrial function, calcium homeostasis, and apoptotic pathways, thus exerting multifaceted effects on cellular fate during ischemic insult [3].

Discussion

Ischemic stroke stands as a formidable global health challenge, being a leading cause of mortality and long-term disability. Despite considerable strides in stroke management, effective therapeutic interventions remain limited. Recent research has unearthed intriguing insights into the role of the PERK (protein kinase RNA-like endoplasmic reticulum kinase) signaling pathway in the pathophysiology of ischemic stroke. This article delves into the intricate molecular mechanisms underlying PERK activation during ischemic insults and explores the promising therapeutic avenues offered by targeting this pathway in stroke management. The emerging recognition of PERK as a critical player in ischemic stroke pathogenesis underscores its therapeutic potential as a druggable target. Pharmacological interventions aimed at modulating PERK activity hold promise in mitigating ischemic brain injury and improving clinical outcomes. Small molecule inhibitors targeting PERK activation or downstream effectors of the PERK pathway offer avenues for neuroprotection and neuroregeneration in ischemic stroke [4]. Furthermore, strategies aimed at harnessing endogenous adaptive mechanisms, such as preconditioning or postconditioning, to enhance PERK-mediated cytoprotection represent innovative approaches in stroke management. Elucidating the mechanisms governing PERK activation and its downstream effects provides valuable insights into novel therapeutic strategies for stroke intervention [5]. Harnessing the therapeutic potential of targeting the PERK pathway holds promise in mitigating neuronal damage, preserving brain function, and improving clinical outcomes in ischemic stroke patients. Further research efforts aimed at unraveling the complexities of PERK signaling and translating these findings into clinical applications is warranted to address the unmet needs in stroke management [6].

Conclusion

The PERK signaling pathway plays a crucial role in the pathophysiology of ischemic stroke, representing a potential therapeutic target for neuroprotection. Targeting PERK-mediated signaling offers a novel approach to mitigate neuronal injury and improve outcomes in ischemic stroke patients. However, addressing the challenges associated with PERK-targeted therapies is essential for their successful translation into clinical practice.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Martin, Seth S., Aaron W. Aday, Zaid I. Almarzooq and Cheryl AM Anderson, et al. “2024 heart disease and stroke statistics: A report of US and global data from the American heart association.”Circ149 (2024): 347-913.

   Google Scholar, Crossref, Indexed at

2. Hetz, Claudio, Kezhong Zhang and Randal J. Kaufman. “Mechanisms, regulation and functions of the unfolded protein response.”Nat Rev Mol Cell Biol21 (2020): 421-438.

   Google Scholar, Crossref, Indexed at

3. Wang, Zhuoran and Wei Yang. “Impaired capacity to restore proteostasis in the aged brain after ischemia: Implications for translational brain ischemia research.”Neurochem Int127 (2019): 87-93.

   Google Scholar, Crossref, Indexed at

4. Yang, Wei and Wulf Paschen. “Unfolded protein response in brain ischemia: A timely update.”J Cereb Blood Flow Metab36 (2016): 2044-2050.

   Google Scholar, Crossref, Indexed at

5. Li, Xuan and Wei Yang. “An update on the unfolded protein response in brain ischemia: Experimental evidence and therapeutic opportunities.”Neurochem Int151 (2021): 105218.

   Google Scholar, Crossref, Indexed at

6. Wang, Lei, Yan Liu, Xu Zhang and Yingze Ye, et al. “Endoplasmic reticulum stress and the unfolded protein response in cerebral ischemia/reperfusion injury.”Front Cell Neurosci16 (2022): 864426.

   Google Scholar, Crossref, Indexed at